Observational analysis reveals 7.5% macrolide resistance in Mycoplasma pneumoniae infections in Southern Italy, highlighting the need for ongoing surveillance.
Key Points
Macrolide resistance was found in 7.5% of Mycoplasma pneumoniae infections.
In May 2025, the prevalence of Mycoplasma pneumoniae peaked at 15.8% among tested samples.
A total of 5362 respiratory specimens underwent testing for pathogens using PCR techniques.
Continued molecular monitoring is essential to combat the spread of macrolide resistance post-pandemic.